{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:18:02Z","timestamp":1794028682299,"version":"4.8.0"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1212\/con.0000000000000700","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T18:52:30Z","timestamp":1549047150000},"page":"14-33","source":"Crossref","is-referenced-by-count":119,"title":["Late-onset Alzheimer Disease"],"prefix":"10.1212","volume":"25","author":[{"given":"Gil D.","family":"Rabinovici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","first-page":"1134","article-title":"Uber eine eigenaritage, schweren Erkrankung der Hirnrinde","volume":"25","author":"Alzheimer A","year":"1907","unstructured":"Alzheimer A. Uber eine eigenaritage, schweren Erkrankung der Hirnrinde. Neurol Zbl 1907;25:1134.","journal-title":"Neurol Zbl"},{"issue":"3","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","article-title":"2018 Alzheimer\u2019s disease facts and figures","volume":"14","author":"Alzheimer\u2019s Association","year":"2018","unstructured":"Alzheimer\u2019s Association. 2018 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2018;14(3):367\u2013429. doi:10.1016\/j.jalz.2018.02.001.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","article-title":"Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Petersen RC","year":"2018","unstructured":"Petersen RC Lopez O Armstrong MJ. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018;90(3):126\u2013135. doi:10.1212\/WNL.0000000000004826.","journal-title":"Neurology"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200110000-00002"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828726f5"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.12.007"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.10.005"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610211002924"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.05.016"},{"issue":"2","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trci.2015.06.004","article-title":"Is late-onset Alzheimer\u2019s disease really a disease of midlife?","volume":"1","author":"Ritchie K","year":"2015","unstructured":"Ritchie K Ritchie CW Yaffe K. Is late-onset Alzheimer\u2019s disease really a disease of midlife? Alzheimers Dement (N Y) 2015;1(2):122\u2013130. doi:10.1016\/j.trci.2015.06.004.","journal-title":"Alzheimers Dement (N Y)"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70072-2"},{"issue":"2","key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrneurol.2013.269","article-title":"Sleep and Alzheimer disease pathology\u2014a bidirectional relationship","volume":"10","author":"Ju YE","year":"2014","unstructured":"Ju YE Lucey BP Holtzman DM. Sleep and Alzheimer disease pathology\u2014a bidirectional relationship. Nat Rev Neurol 2014;10(2):115\u2013119. doi:10.1038\/nrneurol.2013.269.","journal-title":"Nat Rev Neurol"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1115"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3171\/2015.2.JNS14503"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12387"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/B978-0-444-64076-5.00026-0","article-title":"The genetic landscape of Alzheimer disease","volume":"148","author":"Carmona S","year":"2018","unstructured":"Carmona S Hardy J Guerreiro R. The genetic landscape of Alzheimer disease. Handb Clin Neurol 2018;148:395\u2013408. doi:10.1016\/B978-0-444-64076-5.00026-0.","journal-title":"Handb Clin Neurol"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.263"},{"issue":"10","key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","article-title":"Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis","volume":"74","author":"Neu SC","year":"2017","unstructured":"Neu SC Pa J Kukull W. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol 2017;74(10):1178\u20131189. doi:10.1001\/jamaneurol.2017.2188.","journal-title":"JAMA Neurol"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","article-title":"Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer\u2019s diseases","volume":"72","author":"Huang Y","year":"2014","unstructured":"Huang Y Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer\u2019s diseases. Neurobiol Dis 2014;72(pt A):3\u201312. doi:10.1016\/j.nbd.2014.08.025.","journal-title":"Neurobiol Dis"},{"issue":"9","key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.56.9.1143","article-title":"Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"56","author":"Knopman DS","year":"2001","unstructured":"Knopman DS DeKosky ST Cummings JL. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143\u20131153. doi:10.1212\/WNL.56.9.1143.","journal-title":"Neurology"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002258"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30232-1"},{"issue":"4","key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack CR","year":"2018","unstructured":"Jack CRJr Bennett DA Blennow K. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 2018;14(4):535\u2013562. doi:10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Publishing, 2013.","edition":"3"},{"issue":"3","key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann GM","year":"2011","unstructured":"McKhann GM Knopman DS Chertkow H. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 2011;7(3):263\u2013269. doi:10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70090-0"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1017\/S135561771700100X"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002576"},{"issue":"1","key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/CON.0000000000000697","article-title":"Hippocampal sclerosis, argyrophilic grain disease, and primary age-related tauopathy","volume":"25","author":"Jicha GA","year":"2019","unstructured":"Jicha GA Nelson PT. Hippocampal sclerosis, argyrophilic grain disease, and primary age-related tauopathy. Continuum (Minneap Minn) 2019;25(1 Dementia):208\u2013233.","journal-title":"Continuum (Minneap Minn)"},{"issue":"6","key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/1533317512454711","article-title":"Nonamnestic presentations of early-onset Alzheimer\u2019s disease","volume":"27","author":"Mendez MF","year":"2012","unstructured":"Mendez MF Lee AS Joshi A Shapira JS. Nonamnestic presentations of early-onset Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen 2012;27(6):413\u2013420. doi:10.1177\/1533317512454711.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"1","key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1212\/CON.0000000000000696","article-title":"Posterior cortical atrophy","volume":"25","author":"Schott JM","year":"2019","unstructured":"Schott JM Crutch SJ. Posterior cortical atrophy. Continuum (Minneap Minn) 2019;25(1 Dementia):52\u201375.","journal-title":"Continuum (Minneap Minn)"},{"issue":"5","key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jalz.2012.12.001","article-title":"Neuropsychiatric symptoms in Alzheimer\u2019s disease: past progress and anticipation of the future","volume":"9","author":"Geda YE","year":"2013","unstructured":"Geda YE Schneider LS Gitlin LN. Neuropsychiatric symptoms in Alzheimer\u2019s disease: past progress and anticipation of the future. Alzheimers Dement 2013;9(5):602\u2013608. doi:10.1016\/j.jalz.2012.12.001.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3644"},{"issue":"3","key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/brain\/awl377","article-title":"The topography of grey matter involvement in early and late onset Alzheimer\u2019s disease","volume":"130","author":"Frisoni GB","year":"2007","unstructured":"Frisoni GB Pievani M Testa C. The topography of grey matter involvement in early and late onset Alzheimer\u2019s disease. Brain 2007;130(pt 3):720\u2013730. doi:10.1093\/brain\/awl377.","journal-title":"Brain"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-014-9268-3"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.016990"},{"issue":"17","key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.286.17.2120","article-title":"Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome","volume":"286","author":"Silverman DH","year":"2001","unstructured":"Silverman DH Small GW Chang CY. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286(17):2120\u20132127. doi:10.1001\/jama.286.17.2120.","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_2_39_2","first-page":"S45","article-title":"SPECT perfusion imaging in the diagnosis of dementia","volume":"5","author":"Jagust WJ","year":"1995","unstructured":"Jagust WJ Johnson KA Holman BL. SPECT perfusion imaging in the diagnosis of dementia. J Neuroimaging 1995;5(suppl 1):S45\u2013S52. doi:10.1111\/jon19955s1s45.","journal-title":"J Neuroimaging"},{"issue":"2","key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/brain\/awp326","article-title":"Increased metabolic vulnerability in early-onset Alzheimer\u2019s disease is not related to amyloid burden","volume":"133","author":"Rabinovici GD","year":"2010","unstructured":"Rabinovici GD Furst AJ Alkalay A. Increased metabolic vulnerability in early-onset Alzheimer\u2019s disease is not related to amyloid burden. Brain 2010;133(pt 2):512\u2013528. doi:10.1093\/brain\/awp326.","journal-title":"Brain"},{"issue":"10","key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/brain\/awm177","article-title":"FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer\u2019s disease","volume":"130","author":"Foster NL","year":"2007","unstructured":"Foster NL Heidebrink JL Clark CM. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer\u2019s disease. Brain 2007;130(pt 10):2616\u20132635. doi:10.1093\/brain\/awm177.","journal-title":"Brain"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31823b9c5e"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-802395-2.00023-7","article-title":"Alzheimer disease","volume":"145","author":"Calderon-Garcidue\u00f1as AL","year":"2017","unstructured":"Calderon-Garcidue\u00f1as AL Duyckaerts C. Alzheimer disease. Handb Clin Neurol 2017;145:325\u2013337. doi:10.1016\/B978-0-12-802395-2.00023-7.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease","volume":"8","author":"Hyman BT","year":"2012","unstructured":"Hyman BT Phelps CH Beach TG. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement 2012;8(1):1\u201313. doi:10.1016\/j.jalz.2011.10.007.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.12.1791"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31825018f7"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww224"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21706"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001831"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30159-X"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00070-3"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neurobiolaging.2016.02.034","article-title":"Geneva Task Force for the Roadmap of Alzheimer\u2019s Biomarkers. Clinical validity of cerebrospinal fluid A\u03b21-42, tau, and phospho-tau as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"52","author":"Mattsson N","year":"2017","unstructured":"Mattsson N L\u00f6nneborg A Boccardi M; Geneva Task Force for the Roadmap of Alzheimer\u2019s Biomarkers. Clinical validity of cerebrospinal fluid A\u03b21-42, tau, and phospho-tau as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Neurobiol Aging 2017;52:196\u2013213. doi:10.1016\/j.neurobiolaging.2016.02.034.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13195-018-0359-x","article-title":"White paper by the Society for CSF Analysis and Clinical Neurochemistry: overcoming barriers in biomarker development and clinical translation","volume":"10","author":"Teunissen CE","year":"2018","unstructured":"Teunissen CE Otto M Engelborghs S. White paper by the Society for CSF Analysis and Clinical Neurochemistry: overcoming barriers in biomarker development and clinical translation. Alzheimers Res Ther 2018;10(1):30. doi:10.1186\/s13195-018-0359-x.","journal-title":"Alzheimers Res Ther"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2018.9"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4669"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2017.05.058"},{"issue":"5","key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/brain\/aww027","article-title":"Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease","volume":"139","author":"Ossenkoppele R","year":"2016","unstructured":"Ossenkoppele R Schonhaut DR Sch\u00f6ll M. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 2016;139(pt 5):1551\u20131567. doi:10.1093\/brain\/aww027.","journal-title":"Brain"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24546"},{"issue":"3","key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois B","year":"2016","unstructured":"Dubois B Hampel H Feldman HH. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016;12(3):292\u2013323. doi:10.1016\/j.jalz.2016.02.002.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"e_1_3_2_61_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroup","volume":"7","author":"Sperling RA","year":"2011","unstructured":"Sperling RA Aisen PS Beckett LA. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroup. Alzheimers Dement 2011;7(3):280\u2013292. doi:10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"e_1_3_2_62_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert MS","year":"2011","unstructured":"Albert MS DeKosky ST Dickson D. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 2011;7(3):270\u2013279. doi:10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1346"},{"key":"e_1_3_2_64_2","volume-title":"Impact of amyloid PET on patient management: early results from the IDEAS study","author":"Rabinovici GD","year":"2017","unstructured":"Rabinovici GD Gatsonis C Apgar C. Impact of amyloid PET on patient management: early results from the IDEAS study. Alzheimer\u2019s Association International Conference, 2017; London, UK."},{"issue":"5","key":"e_1_3_2_65_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jalz.2014.05.1753","article-title":"Diagnostic impact of CSF biomarkers for Alzheimer\u2019s disease in a tertiary memory clinic","volume":"11","author":"Duits FH","year":"2015","unstructured":"Duits FH Prins ND Lemstra AW. Diagnostic impact of CSF biomarkers for Alzheimer\u2019s disease in a tertiary memory clinic. Alzheimers Dement 2015;11(5):523\u2013532. doi:10.1016\/j.jalz.2014.05.1753.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"e_1_3_2_66_2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"9","author":"Johnson KA","year":"2013","unstructured":"Johnson KA Minoshima S Bohnen NI. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association. Alzheimers Dement 2013;9(1):e1\u2013e16. doi:10.1016\/j.jalz.2013.01.002.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"e_1_3_2_67_2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jalz.2016.03.002","article-title":"Testing and disclosures related to amyloid imaging and Alzheimer\u2019s disease: common questions and fact sheet summary","volume":"12","author":"Rabinovici GD","year":"2016","unstructured":"Rabinovici GD Karlawish J Knopman D. Testing and disclosures related to amyloid imaging and Alzheimer\u2019s disease: common questions and fact sheet summary. Alzheimers Dement 2016;12(4):510\u2013515. doi:10.1016\/j.jalz.2016.03.002.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"e_1_3_2_68_2","doi-asserted-by":"crossref","first-page":"a006395","DOI":"10.1101\/cshperspect.a006395","article-title":"Symptomatic and nonamyloid\/tau based pharmacologic treatment for Alzheimer disease","volume":"2","author":"Aisen PS","year":"2012","unstructured":"Aisen PS Cummings J Schneider LS. Symptomatic and nonamyloid\/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med 2012;2(3):a006395. doi:10.1101\/cshperspect.a006395.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.06.019"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12707"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610209991505"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-11-200706050-00006"},{"issue":"22","key":"e_1_3_2_73_2","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications","volume":"353","author":"Wang PS","year":"2005","unstructured":"Wang PS Schneeweiss S Avorn J. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353(22):2335\u20132341. doi:10.1056\/NEJMoa052827.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_2_74_2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1212\/CON.0000000000000701","article-title":"Prescribing antipsychotic medications to patients with dementia: boxed warnings and mitigation of legal liability","volume":"25","author":"Rose RV","year":"2019","unstructured":"Rose RV Kass JS. Prescribing antipsychotic medications to patients with dementia: boxed warnings and mitigation of legal liability. Continuum (Minneap Minn) 2019;25(1 Dementia):254\u2013259.","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"e_1_3_2_75_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","article-title":"Alzheimer\u2019s disease drug development pipeline: 2017","volume":"3","author":"Cummings J","year":"2017","unstructured":"Cummings J Lee G Mortsdorf T Ritter A Zhong K. Alzheimer\u2019s disease drug development pipeline: 2017. Alzheimers Dement (N Y) 2017;3(3):367\u2013384. doi:10.1016\/j.trci.2017.05.002.","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00132979-201902000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:12:10Z","timestamp":1752156730000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1212\/CON.0000000000000700"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000700","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}